MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR

Abstract

This article has been retracted, and the online PDF replaced with this retraction notice.

Keywords

miR-101 PI3K/Akt/mTOR apoptosis invasion proliferation endometrial cancer

1. Introduction

Endometrial cancer (EC) is one of the common malignant tumors of female reproductive system. At present, there is no satisfactory treatment method for advanced or recurrent patients [1]. PI3K/Akt/mTOR signaling pathway involves in various biological processes, including cell proliferation, apoptosis, migration, invasion, and drug resistance, which is closely related to tumor occurrence, progression, metastasis, and treatment [2, 3]. Drugs targeting PI3K/Akt/mTOR signaling pathway also received more and more attention [2, 4, 5]. Mammals rapamycin target of rapamycin (mTOR), as a downstream molecule of PI3K/Akt pathway, belongs to the serine/threonine protein kinase family. It can promote eIF4E activating target genes through phosphorylating 4EBP1 to remove the combining inhibition between 4EBP1 and eIF4E, thus to play a critical role in regulating cell proliferation, apoptosis, autophagy, and chemotherapy resistance [6]. The enhancement of mTOR expression and activity is correlated with the multiple cancer cell occurrence, progression, and prognosis, such as lung cancer [7], breast cancer [2], prostate cancer [8], and bladder cancer [4]. Several studies demonstrated mTOR overexpression and PI3K/Akt/mTOR signaling pathway enhancement in EC tissue, suggesting that PI3K/ Akt/mTOR pathway abnormal activation is associated with EC [1, 9, 10].

MicroRNA (miRNA) is a kind of small non-coding RNA in eukaryotes at about 22 $\sim$ 25 nucleotides. It can degrade or inhibit target mRNA translation to regulate target gene expression via complete or incomplete complementary binding with the 3’-untranslated region (3’-UTR) of mRNA [11]. MiRNA participates in regulating cell proliferation, apoptosis, and migration by playing a cancer suppressing [12] or promoting [13] role in different cancer cells. MiR-101 is a highly conserved miRNA on evolution located in chromosome 1p31.3 and 9p24.1 [11]. Multiple studies revealed that miR-101 played a inhibition role in intestinal cancer [14], gastric cancer [15], and melanoma [16]. It was shown that miR-101 downregulated in EC tissue, indicating that miR-101 plays a tumor suppressor role in EC [17]. Bioinformatics analysis showed the binding site between miR-101 and the 3’-UTR of mTOR mRNA. This study investigated the role of miR-101 in affecting EC proliferation, apoptosis, and invasion, and mediating mTOR expression.

2. Materials and methods

2.1 Main reagents and materials

EC cell line HEC-1A was purchased from Cellcook (Guangzhou, China). Human normal endometrial epithelial cell (HEEC) was obtained from PriCells (Wuhan, China). DMEM and RPMI 1640 medium were got from Hyclone (USA). Fetal bovine serum was bought from Gemini Bio-Products (USA). Penicillin-streptomycin, L-Glutamine, and sodium pyruvate were provided by CellGro (USA). TriPure RNA Isolation Reagent was purchased from Roche (USA). Lipofectamine RNAiMAX was obtained from Thermo Fisher Scientific. QuantiTect SYBR Green RT-PCR Kit was got from Qiagen (Germany). MiR-101 mimics, miR-NC, and PCR primers were provided by GE Dharmacon. siRNA sequences were synthetized by Genechem (Shanghai, China). Mouse anti human p-mTOR and mTOR monoclonal antibodies were got from CST (USA). Rabbit anti human p-4EBP1 antibody was bought from Abcam (USA). Mouse anti human $\beta$ -actin polyclonal antibody was obtained from GeneTex (USA). HRP labeled goat anti rabbit and mouse IgG (H $+$ L) were got from Molecular Probes (USA). ECL chemiluminescence kit was obtained from Sangon (Shanghai, China). BCA protein quantification kit was purchased from Tiangen (Beijing, China). Matrigel was provided by BD Biosciences (USA). Annexin V-FITD/PI apoptosis detection kit was bought from Beyotime (Jiangsu, China). Psi-CHECK2 plasmid and dual luciferase detection kit were got from Promega (USA).

2.2 Clinical information

A total of 37 cases of EC patients received surgical treatment in Jinan maternity and child care hospital between Nov 2015 and Aug 2016 were enrolled. The median age was 57.2 $\pm$ 3.5 years old ranging from 46 to 67. Based on the FIGO grading criteria 2009, there were 21 patients in stage I, 5 in stage II, 4 in stage III and 5 in stage IV. According to histopathology grading system, 25 patients were in G1, 7 in G2 and 5 in G3. The tumor tissue was collected. All the patients were diagnosed by pathology. Another 22 patients received diagnostic curettage were selected as control with the age range at 48 to 65 years old. No statistical significance was observed on age between two groups.

The study protocol was approved by the Research Ethics Committee of Jinan maternity and child care hospital, and all patients gave their informed consent before study commencement.

2.3 Immunofluorescence

The tissue section was washed by PBS and blocked by serum. Next, it was incubated in mouse anti human mTOR monoclonal antibody (1:300) at 4 ${{}^{\circ}}$ C overnight. Then the section was incubated in Alexa Fluor 488 labeled secondary antibody (1:400) at room temperature. At last, the section was stained by 0.1% DAPI for 1 min and observed under the microscope.

2.4 Cell culture

HEC-1A cells were maintained in DMEM containing 10% FBS, 1% penicillin-streptomycin, and 2 mM L-Glutamine. HEEC cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% sodium pyruvate.

2.5 Dual-luciferase activity detection

The PCR product containing the full length fragment of mTOR 3’-UTR was cloned to psi-CHECK2 plasmid and named as mTOR-UTR-wt. Another luciferase reporter vector containing the mutant of mTOR 3’-UTR was constructed and named as mTOR-UTR-mut. Lipofectamine RNAiMAX was used to co-trans- fect 1 $\mu$ g mTOR-UTR-wt or mTOR-UTR-mut and 50 nmol/L miR-101 mimic to HEK293T cells. After cultured for 48 h, the cells were lysed and tested by Dual-Luciferase ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ Reporter Assay System according to the manual.

2.6 HEC-1A cell transfection

HEC-1A cells were divided into five groups, including miR-NC, miR-101 mimic, si-NC, si-mTOR, and miR-101 $+$ si-mTOR. The cells were transfected after 72 h cultivation. Si-mTOR sense strand, 5 ${}^{\prime}$ -GT AAATGCTTCCACTAAACdTdT-3 ${}^{\prime}$ . Si-mTOR antisense strand, 5 ${}^{\prime}$ -GTTTAGTGGAAGCATTTACdTdT-3 ${}^{\prime}$ . Si-NC sense strand, 5 ${}^{\prime}$ -TTCTCCGAACGTGTCAC GTdTdT-3 ${}^{\prime}$ . Si-NC antisense strand, 5 ${}^{\prime}$ -ACGTGACAC GTTCGGAGAAdTdT-3 ${}^{\prime}$ .

2.7 qRT-PCR

Total RNA was extracted using the TriPure RNA Isolation Reagent kit. QuantiTect SYBR Green RT-PCR Kit was applied for qRT-PCR detection. The qRT-PCR reaction system contained 10.0 $\mu$ l 2 $\times$ QuantiTect SYBR Green RT-PCR Master Mix, 1.0 $\mu$ l primers at 0.5 $\mu$ m/L, 2 $\mu$ g Template RNA, 0.5 $\mu$ l QuantiTect RT Mix, and ddH ${}_{2}$ O. The primers used were as follows. miR-101P ${}_{F}$ : 5 ${}^{\prime}$ -GAGGGGTACAGTACTGTGATA-3 ${}^{\prime}$ , miR-101P ${}_{R}$ : 5 ${}^{\prime}$ -TGCGTGTCGTGGAGTC-3 ${}^{\prime}$ ; U6P ${}_{F}$ : 5 ${}^{\prime}$ -ATTGGAACGATACAGAGAAGATT-3 ${}^{\prime}$ , U6P ${}_{R}$ : 5 ${}^{\prime}$ -GGAACGCTTCACGAATTTG-3 ${}^{\prime}$ ; mTORP ${}_{F}$ : 5 ${}^{\prime}$ -G CAGATTTGCCAACTATCTTCGG-3 ${}^{\prime}$ , mTORP ${}_{R}$ : 5 ${}^{\prime}$ -CAGCGGTAAAAGTGTCCCCTG-3 ${}^{\prime}$ ; $\beta$ -actinP ${}_{F}$ : 5 ${}^{\prime}$ -GAACCCTAAGGCCAAC-3 ${}^{\prime}$ , $\beta$ -actinP ${}_{R}$ : 5 ${}^{\prime}$ -TGTCA CGCACGATTTCC-3 ${}^{\prime}$ . The reverse transcription was performed at 50 ${{}^{\circ}}$ C for 30 min. The PCR reaction was composed of 95 ${{}^{\circ}}$ C for 15 min, followed by 40 cycles of 94 ${{}^{\circ}}$ C for 15 s, 60 ${{}^{\circ}}$ C for 30 s, and 72 ${{}^{\circ}}$ C for 30 s.

2.8 Western blot

The cells were lysed by SDS containing 1 mM PMSF and transferred to the 1.5 ml EP tube. After centrifuged at 10000 g and 4 ${{}^{\circ}}$ C for 5 min, the protein was separated by 10% SDS-PAGE. After the protein was transferred to PVDF membrane, the membrane was blocked in 5% skim mile at room temperature for 60 min. Next, the membrane was incubated in primary antibody (p-mTOR, mTOR, p-4EBP1, and $\beta$ -actin at 1:100, 1:200, 1:100, and 1:500) at 4 ${{}^{\circ}}$ C overnight. After washed by PBST for three times, the membrane was further incubated in HRP labeled secondary antibody (1:500) at room temperature for 60 min. At last, the membrane was treated by ECL and detected.

2.9 Flow cytometry

The cells were collected by 0.25% enzyme without EDTA and transferred to 15 ml centrifuge tube. Next, the cells were added to 300 $\mu$ l Binding Buffer. After incubated in 5 $\mu$ l Annexin V-FITC and 5 $\mu$ l PI avoid of light for 15 min, the sample was added with 200 $\mu$ l Binding Buffer and tested on the flow cytometry.

2.10 Cell invasion assay

Boyden Chamber Assay was used to test cell invasion. A total of 1 $\times$ 10 ${}^{5}$ cells were resuspended in 600 $\mu$ l serum free DMEM and seeded in the upper chamber containing Matrigel. Another 600 $\mu$ l DMEM containing 10% FBS were added to the lower chamber. After 48 h incubation, the unpenetrated cells and Matrigel were removed. The penetrated cells were fixed by methanol and stained by 0.1% crystal violet. At last, the membrane was observed under the microscope.

2.11 Colony formation assay

The cells were seeded in the 10 cm dish at 100/dish. After 2–3 weeks, the cells were fixed by 4% parafor- maldehyde and stained by Giemsa. The colony formation rate $=$ clone number/seeded number $\times$ 100%.

2.12 Statistical analysis

All data analysis was performed on SPSS 18.0 software. All population has a normal distribution. The measurement data were depicted as mean $\pm$ standard deviation. Student unpaired t-test was performed for comparison of the difference between two groups. One-way ANOVA with Newman-Keuls multiple comparison post-hoc analysis was performed for comparison among different groups. $P<$ 0.05 was considered as statistical significance.

Figure 1.

MiR-101 declined, while mTOR upregulated in EC tissue and cell line. (A) qRT-PCR detection of gene expression; (B) Immunofluorescence detection of mTOR protein expression; (C) The binding site between miR-101 and the 3’-UTR of mTOR mRNA; (D) Dual luciferase reporter gene assay.

Figure 2.

MiR-101 downregulation was related to the enhancement of mTOR and 4EBP1 phosphorylation in HEC-1A cells. (A) qRT-PCR detection of gene expression; (B) Western Blot detection of protein expression; (C) qRT-PCR detection of gene expression; (D) Western Blot detection of protein expression.

3. Results

3.1 MiR-101 declined, while mTOR upregulated in EC tissue and cell line

qRT-PCR detection showed that miR-101 expression significantly declined in EC tissue compared with normal endometrial tissue (Fig. 1A). Immunofluorescence detection revealed that mTOR expression was obviously higher in EC tissue than the normal control (Fig. 1B). It suggested that miR-101 may target mTOR. MiR-101 downregulation may play a role in elevating mTOR expression and promoting EC pathogenesis. microRNA.org online prediction demonstrated the complimentary binding site between miR-101 and the 3’-UTR of mTOR mRNA (Fig. 1C). Dual luciferase reporter gene assay exhibited that miR-101 overexpression markedly reduced the relative luciferase activity in HEK293T cells (Fig. 1D), confirming the targeted relationship between miR-101 and mTOR.

Figure 3.

MiR-101 upregulation attenuated mTOR activity, cell invasion, and proliferation, and facilitated cell apoptosis. (A) qRT-PCR detection of gene expression; (B) Western Blot detection of protein expression; (C) Colony formation assay; (D) Transwell assay detection of cell invasion; (E) Flow cytometry detection of cell apoptosis. a. $P<$ 0.05, compared with miR-NC; b. $P<$ 0.05, compared with si-NC; c. $P<$ 0.05, compared with miR-NC; d. $P<$ 0.05, compared with si-NC.

3.2 MiR-101 downregulation was related to the enhancement of mTOR and 4EBP1 phosphorylation in HEC-1A cells

qRT-PCR results showed that miR-101 reduced, while mTOR mRNA upregulated in HEC-1A cells compared with HEEC cells (Fig. 2A). Western blot exhibited that mTOR, p-mTOR, and p-4EBP1 levels markedly elevated in HEC-1 cells compared with HEEC cells (Fig. 2B). MiR-101 mimics significantly decreased mTOR mRNA expression in HEC-1A cells (Fig. 2C), leading to mTOR, p-mTOR, and p-4EBP1 protein levels reduction (Fig. 2D). It indicated that mTOR activity enhancement in EC cells was based on mTOR upregulation.

3.3 MiR-101 upregulation attenuated mTOR activity, cell invasion, and proliferation, and facilitated cell apoptosis

MiR-101 mimic and/or si-mTOR transfection obviously reduced mTOR (Fig. 3A), p-mTOR, and p-4EBP1 (Fig. 3B) expressions, decreased colony formation (Fig. 3C), decreased invasion (Fig. 3D), and enhanced apoptosis (Fig. 3E) in HEC-1A cells.

4. Discussion

The pathogenesis of EC is complicated and has not been fully elucidated. Therefore, in-depth investigation of the EC pathogenesis is of great significance to help diagnose, enhance the curative effect, and improve prognosis. Signaling pathway composed of extracellular ligands, cell receptors, and a series of downstream molecular cascade can regulate a variety of biological processes. The role of abnormal signal transduction in tumor receives more and more attention. PI3K/Akt is the most important protein located at the upstream of mTOR. PI3K/Akt/mTOR signaling pathway is the main dependent pathway to help mTOR plays a regulatory role. PI3K/Akt/mTOR signaling pathway has been confirmed to play an important role in tumor pathogenesis as it participates in the regulation of multiple biological processes, such as cell proliferation, cycle, apoptosis, and invasion [2, 3]. Phosphatidylinositol-3 kinase (PI3K) auto-conformation change was activated under the stimulation of growth factor, mitogen, and other signaling molecules. Activated PI3K can promote phosphatidylinositol(4,5)-bisphosphate (PIP2)phosphorylation to phosphatidylinositol(3,4,5)-trisph- osphate (PIP3) through its p110 catalytic subunit. PIP3 can act on the PH domain of Akt/PKB to change conformation. Moreover, it can phosphorylate Akt at Ser473 and Thr308 under the effect of PDK1 and PDK2. Activated Akt kinase further phosphorylated mTOR (mTORC1 and mTORC2), leading to it binding with the eIF-4E binding protein1 (4EBP1) on eukaryotic initiation factor 4E (eIF-4E). The 4EBP1 was phosphorylated and reduced affinity with eIF-4E, thus blocking the suppression of 4EBP1 on eIF-4E binding and translation. Dissociative eIF-4E band with eIF-4G/eIF-4A/eIF-4B to form eIF-4F complex and further coupled to the cap structure of mRNA 5’-terminal. It promoted mRNA translation and protein synthesis, thus accelerating cell cycle and mitosis proliferation [18]. In addition to cell proliferation and cycle, PI3K/Akt/mTOR also plays an inhibitory role on cell apoptosis through acting on Bax/Bcl-2 [19]. Moreover, mTORC2 participates in Akt protein activation via Ser473 phosphorylation, thus forming the positive feedback of PI3K/Akt/mTOR pathway [20]. Several studies showed that mTOR enhancement exhibited tumorpromoting role in EC occurrence [21, 22]. The inhibitors targeting mTOR demonstrated the antitumor effect on EC [23]. the expression and function of mTOR increase in the incidence of endometrial carcinoma showed the role that promote cancer, and with the targets of mTOR inhibitors are showed on the anti-tumor effect of endometrial carcinoma [23]. It was revealed that miR-101 markedly decreased in EC tissue [17], suggesting that miR-101 also played a tumor suppressor role in EC. Bioinformatics analysis showed the binding site between miR-101 and the 3’-UTR of mTOR mRNA. This study investigated the role of miR-101 in affecting EC cell line HEC-1A proliferation, apoptosis, and invasion, and mediating mTOR expression.

Our results demonstrated that miR-101 level obviously reduced, while mTOR significantly upregulated in EC tissue compared with normal endometrium, suggesting their potential targeted regulatory relationship. Dual luciferase report gene assay confirmed the targeted regulatory relationship between miR-101 and mTOR. Hiroki et al. [24] reported that miR-101 level significantly declined in EC tissue compared with normal endometrium. Patients with lower expression level showed shorter progression free survival. Thus, miR-101 could be treated as the independent predictor of survival and prognosis. Konno et al. [25] exhibited that miR-101 expression markedly downregulated in EC tissue compared with para-carcinoma tissue. Hiroki et al. [26] also found miR-101 downregulation in EC tissue through microarray screening. Our study demonstrated miR-101 was significantly decreased in EC tissue compared with control, which was in accordance with Hiroki [24] and Konno [25]. In addition, miR-101 abnormal reduction was also found in EC cell line HEC-1A. Konno et al. [25] discovered that miR-101 declined in EC cell line SPAC-1-L, HEC-50, and HOUA-I compared with normal endometrial epithelial cells, which was similar to our results. Elevated miR-101 markedly reduced mTOR, p-mTOR, and p-4EBP1 expressions in HEC-1A cells, indicating that mTOR phosphorylation enhancement was the reason of mTOR upregulation in EC cells. Further investigation found that miR-101 mimic and/or si-mTOR transfection obviously reduced mTOR, p-mTOR, and p-4EBP1 expressions, decreased colony formation, decreased invasion, and enhanced apoptosis in HEC-1A cells. Hiroki et al. [24] showed that miR-101 upregulation apparently inhibited EC cell line SPAC-1-L proliferation. Konno et al. [25] reported that miR-101 overexpression obviously restrained EC cell proliferation and induced apoptosis and senescence. Konno et al. [25] also demonstrated that miR-101 can suppress the epithelial-mesenchymal transition (EMT) and attenuated tumor cell migration and invasion. Bae-Jump et al. revealed that mTOR siRNA significantly enhanced Ishikawa and ECC-1 cell apoptosis induced by cisplatin. All of these researches reported that miR-101 upregulation or mTOR reduction may attenuate the malignant biological characteristic of EC cells. This study demonstrated that miR-101 downregulation promoted EC pathogenesis by enhancing PI3K/Akt/mTOR signaling pathway.

5. Conclusion

MiR-101 downregulated and mTOR elevated in EC tissue. MiR-101 decreased HEC-1A cell proliferation and invasion, and upregulated apoptosis through targeting mTOR to attenuate PI3K/Akt/mTOR signaling pathway activity.

References

Zhang

Lin

Luo

Xiao

and Zhou

, A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma, Am J Transl Res 8 (2016), 719–731.

Guerrero-Zotano

Mayer

I.A.

and Arteaga

C.L.

, PI3K/ AKT/mTOR: Role in breast cancer progression drug resistance and treatment, Cancer Metastasis Rev (2016).

Ilagan

and Manning

B.D.

, Emerging role of mTOR in the response to cancer therapeutics, Trends Cancer 2 (2016), 241–251.

Pinto-Leite

Arantes-Rodrigues

Sousa

Oliveira

P.A.

and Santos

, mTOR inhibitors in urinary bladder cancer, Tumour Biol 37 (2016), 11541–11551.

Xie

Wang

and Proud

C.G.

, mTOR inhibitors in cancer therapy, F1000Res (2016), 5.

Nogami

Oshikawa

Okada

Fukutake

Umezawa

Nagao

Kurosu

and Miura

, FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia, Oncotarget 6 (2015), 9189–9205.

Zhao

Yang

Yao

Xiao

Cheng

Feng

Duan

Zhang

Liu

and Dai

, Unfolded protein response promotes doxorubicin-induced nonsmall-cell lung cancer cells apoptosis via the mTOR pathway inhibition, Cancer Biother Radiopharm (2016).

Xia

Zheng

Jiang

Huang

Wang

Rodriguez

and Jin

, Valproic acid induces autophagy by suppressing the akt/mTOR pathway in human prostate cancer cells, Oncol Lett 12 (2016), 1826–1832.

Pavlidou

and Vlahos

N.F.

, Molecular alterations of PI3K/ Akt/mTOR pathway: A therapeutic target in endometrial cancer, Scientific World Journal 2014 (2014), 709736.

10.

J.H.

Jeon

Y.T.

Park

I.A.

Kang

Kim

J.W.

Park

N.H.

Kang

S.B.

and Song

Y.S.

, Expression of mTOR protein and its clinical significance in endometrial cancer, Med Sci Monit 15 (2009), BR301–BR305.

11.

Gui

and Shen

, miRNA-101: A potential target for tumor therapy, Cancer Epidemiol 36 (2012), 537–540.

12.

Chen

Sun

K.X.

Liu

B.L.

Zong

Z.H.

and Zhao

, MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-alpha, Mol Cancer 15 (2016), 11.

13.

Mitamura

Watari

Wang

Kanno

Kitagawa

Hassan

M.K.

Kimura

Tanino

Nishihara

Tanaka

and Sakuragi

, MicroRNA 31 functions as an endometrial cancer oncogene by suppressing hippo tumor suppressor pathway, Mol Cancer 13 (2014), 97.

14.

Strillacci

Griffoni

Sansone

Paterini

Piazzi

Lazzarini

Spisni

Pantaleo

M.A.

Biasco

and Tomasi

, MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells, Exp Cell Res 315 (2009), 1439–1447.

15.

Wang

H.J.

Ruan

H.J.

X.J.

Y.Y.

Jiang

X.T.

Xia

Y.J.

Z.Y.

and Tao

H.Q.

, MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion, Eur J Cancer 46 (2010), 2295–2303.

16.

Luo

Merz

P.R.

Chen

Dickes

Pscherer

Schadendorf

and Eichmuller

S.B.

, MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2, Cancer Lett 341 (2013), 240–247.

17.

Cai

Lin

Tang

and Wang

, Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor progression and prognosis in pediatric osteosarcoma, Int J Mol Sci 15 (2014), 560–573.

18.

Darb-Esfahani

Faggad

Noske

Weichert

Buckendahl

A.C.

Muller

Budczies

Roske

Dietel

and Denkert

, Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: Association with stage and grade in vivo and link with response to rapamycin treatment in vitro, J Cancer Res Clin Oncol 135 (2009), 933–941.

19.

Choudhary

G.S.

Al-Harbi

Mazumder

Hill

B.T.

Smith

M.R.

Bodo

Hsi

E.D.

and Almasan

, MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies, Cell Death Dis 6 (2015), e1593.

20.

Zhang

Liu

Geng

Wang

Gan

Guo

Chin

Y.R.

Berrios

Lien

E.C.

Toker

DeCaprio

J.A.

Sicinski

and Wei

, Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of akt, Mol Cell 62 (2016), 929–942.

21.

Shoji

Oda

Kashiyama

Ikeda

Nakagawa

Sone

Miyamoto

Hiraike

Tanikawa

Miyasaka

Koso

Matsumoto

Wada-Hiraike

Kawana

Kuramoto

McCormick

Aburatani

Yano

Kozuma

and Taketani

, Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor NVP-BEZ235 and an mTOR inhibitor RAD001 in endometrial carcinomas, PLoS One 7 (2012), e37431.

22.

Korets

S.B.

Musa

Curtin

Blank

S.V.

and Schneider

R.J.

, Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer, Gynecol Oncol 132 (2014), 468–473.

23.

Husseinzadeh

and Husseinzadeh

H.D.

, mTOR inhibitors and their clinical application in cervical endometrial and ovarian cancers: A critical review, Gynecol Oncol 133 (2014), 375–381.

24.

Hiroki

Akahira

Suzuki

Nagase

Ito

Suzuki

Sasano

and Yaegashi

, Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas, Cancer Sci 101 (2010), 241–249.

25.

Konno

Dong

Xiong

Suzuki

Cai

Watari

Mitamura

Hosaka

Hanley

S.J.

Kudo

and Sakuragi

, MicroRNA-101 targets EZH2 MCL-1 and FOS to suppress proliferation invasion and stem cell-like phenotype of aggressive endometrial cancer cells, Oncotarget 5 (2014), 6049–6062.

26.

Hiroki

Suzuki

Akahira

Nagase

Ito

Sugawara

Miki

Suzuki

Sasano

and Yaegashi

, MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma, Int J Cancer 131 (2012), E395–E404.

27.

Bae-Jump

V.L.

Zhou

Boggess

J.F.

and Gehrig

P.A.

, Synergistic effect of rapamycin and cisplatin in endometrial cancer cells, Cancer 115 (2009), 3887–3896.